We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
SINNOWA MEDICAL SCIENCE & TECH

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Jan 2021 - 27 Jan 2021
Virtual Venue
24 Feb 2021 - 28 Feb 2021
Virtual Venue

Predicting Thrombosis Risk in SLE Patients by Monitoring Blood Levels of Hydroxychloroquine

By LabMedica International staff writers
Posted on 12 Jan 2021
Print article
Image: Ball-and-stick model of a hydroxychloroquine molecule (Photo courtesy of Wikimedia Commons)
Image: Ball-and-stick model of a hydroxychloroquine molecule (Photo courtesy of Wikimedia Commons)
Risk of developing a blood clot (thrombosis) by patients suffering from systemic lupus erythematosus can be predicted by monitoring levels of hydroxychloroquine in the blood.

Systemic lupus erythematosus (SLE) is an autoimmune disease triggered by genetic and environmental factors in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, fatigue, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms. The anti-malaria drug hydroxychloroquine (HCQ) has a primary role in the prophylaxis and treatment of systemic lupus erythematosus (SLE) and may be protective against thrombosis in SLE.

Investigators at Johns Hopkins University (Baltimore, MD, USA) examined the usefulness of HCQ blood monitoring in predicting thrombosis risk in a longitudinal SLE cohort. For this study, the investigators used liquid chromatography‐tandem mass spectrometry to measure levels of HCQ in EDTA whole blood samples taken from 739 patients with SLE.

Results revealed that clotting occurred in 38 patients (5.1%). Average HCQ blood levels were lower in patients who developed clots, and clotting rates were reduced by 12% for every 200 nanograms per milliliter increase in the most recent HCQ blood level. Thrombotic events were reduced by 69% in patients with mean HCQ blood levels greater than 1068 nanograms per milliliter versus less than 648 nanograms per milliliter.

Low HCQ blood levels were associated with thrombotic events in SLE. "Hydroxychloroquine blood levels can be used to monitor adherence, benefits, and risks in lupus," said first author Dr. Michelle Petri, professor of medicine at Johns Hopkins University.

The hydroxychloroquine paper was published in the January 5, 2021, online edition of the journal Arthritis & Rheumatology.

Related Links:
Johns Hopkins University


Print article

Channels

Industry

view channel
Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.